A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Refractory, EGFR-Negative Metastatic Colorectal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2010
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImClone Systems
- 31 Aug 2018 Biomarkers information updated
- 27 Oct 2009 Primary outcomes amended from ClinicalTrials.gov record.
- 10 Dec 2008 Status changed from active, no longer recruiting to completed.